JP2023153863A5 - - Google Patents

Info

Publication number
JP2023153863A5
JP2023153863A5 JP2023118782A JP2023118782A JP2023153863A5 JP 2023153863 A5 JP2023153863 A5 JP 2023153863A5 JP 2023118782 A JP2023118782 A JP 2023118782A JP 2023118782 A JP2023118782 A JP 2023118782A JP 2023153863 A5 JP2023153863 A5 JP 2023153863A5
Authority
JP
Japan
Prior art keywords
methods
new products
manufacturing methods
manufacturing
methods substantially
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023118782A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023153863A (ja
Filing date
Publication date
Priority claimed from JP2019214063A external-priority patent/JP2020063259A/ja
Application filed filed Critical
Publication of JP2023153863A publication Critical patent/JP2023153863A/ja
Publication of JP2023153863A5 publication Critical patent/JP2023153863A5/ja
Pending legal-status Critical Current

Links

JP2023118782A 2015-12-18 2023-07-21 15-hepeを含む組成物及びその使用方法 Pending JP2023153863A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562269280P 2015-12-18 2015-12-18
US62/269,280 2015-12-18
JP2019214063A JP2020063259A (ja) 2015-12-18 2019-11-27 15−hepeを含む組成物及びその使用方法
JP2021118532A JP2021178840A (ja) 2015-12-18 2021-07-19 15−hepeを含む組成物及びその使用方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021118532A Division JP2021178840A (ja) 2015-12-18 2021-07-19 15−hepeを含む組成物及びその使用方法

Publications (2)

Publication Number Publication Date
JP2023153863A JP2023153863A (ja) 2023-10-18
JP2023153863A5 true JP2023153863A5 (https=) 2026-01-14

Family

ID=57995240

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018531629A Pending JP2018537513A (ja) 2015-12-18 2016-12-19 15−hepeを含む組成物及びその使用方法
JP2019214063A Pending JP2020063259A (ja) 2015-12-18 2019-11-27 15−hepeを含む組成物及びその使用方法
JP2021118532A Pending JP2021178840A (ja) 2015-12-18 2021-07-19 15−hepeを含む組成物及びその使用方法
JP2023118782A Pending JP2023153863A (ja) 2015-12-18 2023-07-21 15-hepeを含む組成物及びその使用方法

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2018531629A Pending JP2018537513A (ja) 2015-12-18 2016-12-19 15−hepeを含む組成物及びその使用方法
JP2019214063A Pending JP2020063259A (ja) 2015-12-18 2019-11-27 15−hepeを含む組成物及びその使用方法
JP2021118532A Pending JP2021178840A (ja) 2015-12-18 2021-07-19 15−hepeを含む組成物及びその使用方法

Country Status (18)

Country Link
US (5) US9855238B2 (https=)
EP (2) EP4218736A3 (https=)
JP (4) JP2018537513A (https=)
KR (6) KR20230047501A (https=)
CN (2) CN108697680A (https=)
AR (2) AR107143A1 (https=)
AU (4) AU2016370626B2 (https=)
BR (1) BR122023026625A2 (https=)
CA (2) CA3129008A1 (https=)
ES (1) ES2948444T3 (https=)
IL (3) IL294736A (https=)
MX (2) MX379262B (https=)
NZ (1) NZ744323A (https=)
PH (1) PH12018501279A1 (https=)
RU (2) RU2020137883A (https=)
SG (1) SG11201805149XA (https=)
WO (1) WO2017103671A1 (https=)
ZA (2) ZA201804779B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
JP2016538288A (ja) 2013-11-15 2016-12-08 ディグニティ サイエンシス リミテッド 多価不飽和ヒドロキシ脂肪酸の薬学的に許容される塩
MA41120A (fr) 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
MA47141A (fr) 2015-05-13 2019-11-06 Ds Biopharma Ltd Compositions comprenant du15-oxo-epa ou du 15-oxo-dgla et leurs procédés de préparation et d'utilisation
ES2851525T3 (es) 2015-07-21 2021-09-07 Afimmune Ltd Composiciones que comprenden 15(S)-HEPE para su uso en la sensibilización de las células cancerosas a la radioterapia
CA3129008A1 (en) * 2015-12-18 2017-06-22 Afimmune Limited Compositions comprising 15-hepe and methods of using the same
CN113116878A (zh) * 2020-01-10 2021-07-16 南京大学 15s-hepe用于增强t细胞介导的肿瘤免疫治疗的新用途
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
US11622495B2 (en) 2021-06-01 2023-04-11 Gint Co., Ltd. Method of automatically combining farm vehicle and work machine and farm vehicle
CN113855659B (zh) * 2021-11-24 2022-12-23 中国人民解放军东部战区总医院 12-hepe或其药学上可接受的脂肪酸改善精子发生障碍的应用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05186342A (ja) * 1992-01-10 1993-07-27 Fujirebio Inc 免疫調節作用を併せもつ抗炎症剤
GB9301446D0 (en) 1993-01-26 1993-03-17 Scotia Holdings Plc Internal radiation damage
AU683027B2 (en) 1993-01-27 1997-10-30 Scotia Holdings Plc Triglycerides
JPH09505562A (ja) 1993-10-01 1997-06-03 アール.ピー.シェーラー コーポレイション 香料を小分けして提供する方法および組成物
GB9715444D0 (en) 1997-07-22 1997-09-24 Scotia Holdings Plc Therapeutic and dietary compositions
JP2000191525A (ja) 1998-12-25 2000-07-11 Nof Corp 皮膚外用剤組成物
EP1762557B1 (en) 2000-02-16 2011-04-06 The Brigham And Women's Hospital, Inc. Aspirin-triggered lipid mediators
US20020188024A1 (en) 2000-08-23 2002-12-12 Chilton Floyd H. Fatty acid-containing emulsion with increased bioavailability
US20040043013A1 (en) 2000-12-28 2004-03-04 Mccleary Edward Larry Metabolic uncoupling therapy
ATE291910T1 (de) 2001-05-30 2005-04-15 Laxdale Ltd Verwendung von coenzym q (ubiquinone) und eikosapentaensäure (epa) für die behandlung von non-hodgkin's lymphoma und psychiatrischen oder neurologischen erkrankungen
KR20050083960A (ko) 2002-11-22 2005-08-26 닛폰 스이산 가부시키가이샤 고도 불포화 지방산, 그 염, 또는 그 에스테르를 함유하는외용 조성물
JP2005179211A (ja) 2003-12-17 2005-07-07 Idemitsu Kosan Co Ltd 皮膚外用剤組成物
EP1711173A2 (en) 2003-12-31 2006-10-18 Igennus Limited Formulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or ester thereof
WO2005102309A2 (en) 2004-04-26 2005-11-03 Ltb4 Sweden Ab In vivo release of endogenous anti-microbial mediators by leukotriene b4 (ltb4) administration
AU2005262392A1 (en) 2004-07-01 2006-01-19 Johnson & Johnson Vision Care, Inc. Compositions and methods for treating eye disorders and conditions
US7666447B2 (en) 2004-10-08 2010-02-23 Pharmanutrients Compositions including Krill extracts and conjugated linoleic acid and methods of using same
US7893106B2 (en) 2004-11-19 2011-02-22 Martek Biosciences, Corporation Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same
JP5504405B2 (ja) * 2005-06-10 2014-05-28 国立大学法人山口大学 血管病予防に効果を有する食品組成物
EP3285072B1 (en) 2006-08-08 2020-04-15 Metabolon, Inc. Markers of non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash) and methods of use thereof
GB0802116D0 (en) 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
US20110105510A1 (en) 2008-06-17 2011-05-05 Hiroshi Ishikawa Prophylactic/ameliorating or therapeutic agent for non-alcoholic steatohepatitis
JP2010229099A (ja) * 2009-03-27 2010-10-14 Mochida Pharmaceut Co Ltd 脂質異常症の改善または治療薬
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
CA2972063C (en) * 2009-05-22 2019-12-17 Mochida Pharmaceutical Co., Ltd. Self-emulsifying composition of .omega.3 fatty acid
CA2690488C (en) 2010-01-19 2013-06-11 Accucaps Industries Limited Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof
US10154977B2 (en) 2011-03-25 2018-12-18 The Brigham And Women's Hospital, Inc. Anti-inflammatory particles
US20120264824A1 (en) 2011-04-15 2012-10-18 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
RU2014119948A (ru) 2011-10-19 2015-11-27 Дигнити Сайенсиз Лимитед ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ DGLA И/ИЛИ 15-HETrE, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
JP2015500639A (ja) 2011-11-29 2015-01-08 ディグニティ サイエンシス リミテッド 20−炭素脂肪酸を含む組成物ならびにその製造方法および使用方法
RS57777B1 (sr) 2012-01-06 2018-12-31 Omthera Pharmaceuticals Inc Dpa-obogaćene kompozicije omega-3 polinezasićenih masnih kiselina u obliku slobodne kiseline
US20120264705A1 (en) 2012-01-26 2012-10-18 Dignity Sciences Limited Antimicrobial compositions comprising 15-hetre and methods of use thereof
US20130267598A1 (en) 2012-02-23 2013-10-10 Dignity Sciences Limited Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same
JP6359517B2 (ja) * 2012-03-30 2018-07-18 サンシリオ アンド カンパニー, インコーポレイテッドSancilio & Company, Inc. ω−3脂肪酸エステル組成物
WO2013150386A2 (en) 2012-04-04 2013-10-10 Pronova Biopharma Norge As Compositions comprising omega-3 fatty acids and vitamin d for acne vulgaris and/or eczema, and methods and uses thereof
DK2858496T3 (da) * 2012-05-10 2023-07-24 Solutex Na Llc Olier med anti-inflammatorisk aktivitet, som indeholder naturlige specialiserede pro-afhjælpningsmediatorer og deres forløbere
GB201213484D0 (en) * 2012-07-30 2012-09-12 Dignity Sciences Ltd Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
WO2015008848A1 (ja) * 2013-07-18 2015-01-22 持田製薬株式会社 ω3脂肪酸の自己乳化組成物
JP2016538288A (ja) * 2013-11-15 2016-12-08 ディグニティ サイエンシス リミテッド 多価不飽和ヒドロキシ脂肪酸の薬学的に許容される塩
EP3091959A4 (en) * 2014-01-10 2017-09-20 Dignity Sciences Limited Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
MA41120A (fr) * 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
US20180008567A1 (en) * 2015-01-16 2018-01-11 Afimmune Limited Compositions comprising 15-hepe and methods of using the same
MA47141A (fr) * 2015-05-13 2019-11-06 Ds Biopharma Ltd Compositions comprenant du15-oxo-epa ou du 15-oxo-dgla et leurs procédés de préparation et d'utilisation
ES2851525T3 (es) * 2015-07-21 2021-09-07 Afimmune Ltd Composiciones que comprenden 15(S)-HEPE para su uso en la sensibilización de las células cancerosas a la radioterapia
CA3129008A1 (en) * 2015-12-18 2017-06-22 Afimmune Limited Compositions comprising 15-hepe and methods of using the same

Similar Documents

Publication Publication Date Title
JP2023113641A5 (https=)
JP2024156852A5 (https=)
JP2024133471A5 (https=)
JP2026012786A5 (https=)
JP2024037765A5 (https=)
JP2023113681A5 (https=)
JP2025023938A5 (https=)
JP2023164986A5 (https=)
JP2023153863A5 (https=)
JP2026048925A5 (https=)
JP2022538004A5 (https=)
JP2025106258A5 (https=)
JP2023134519A5 (https=)
JP2023103231A5 (https=)
JP2025118771A5 (https=)
JP2024156705A5 (https=)
JP2025038009A5 (https=)
JP2024088648A5 (https=)
JP2023139025A5 (https=)
JP2023154065A5 (https=)
JP2018100276A5 (https=)
JP2025143267A5 (https=)
JP2024160274A5 (https=)
JP2025163046A5 (https=)
JP2025124655A5 (https=)